Ryugaku Jinja · Professor Archive
Public Professor Archive
Shinichiro Kawamoto川本 晋一郎
Kobe University · University Hospital · 講師
- Publications
- 4
- Projects
- 2
- Keywords
- 6
留学
神社Kobe University · University Hospital · 講師
Research keywordshematopoietic stem cell transplantation・sinusoidal obstruction syndrome・vaccine immunogenicity・synbiotics・continuous glucose monitoring・transplant complication management
This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.
- 日常的に計算可能な臨床的指標と、類洞閉塞症候群(SOS/VOD)の病勢進行との関連2024 · (一社)日本血液学会, 2024年10月, 日本血液学会学術集会, 86回, O2 - 3, 英語
- 自己免疫性溶血性貧血の病因・病態・診断・治療2024 · 2024年10月, 65(9) (9), 892 - 901
- Utility of the refined EBMT diagnostic and severity criteria 2023 for sinusoidal obstruction syndrome/veno-occlusive disease2024 · 2024年09月, Bone Marrow Transplant., 59(4) (4), 518 - 525, 英語
- Analysis of B-cell receptor repertoire to evaluate immunogenicity of monovalent Omicron XBB.1.5 mRNA vaccines.2023 · Monovalent Omicron XBB.1.5 mRNA vaccines were newly developed and approved by the FDA in Autumn 2023 for preventing COVID-19. However, clinical efficacy for these vaccines is currently lacking. We previously established the quantification of antigen-specific antibody sequence (QASAS) method to assess the response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the coronavirus antibody database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of monovalent XBB.1.5 vaccines. We analyzed repeated blood samples of healthy volunteers before and after monovalent XBB.1.5 vaccination (BNT162b2 XBB.1.5 or mRNA-1273.815) for the BCR repertoire to assess BCR/antibody sequences that matched SARS-CoV-2-specific sequences in the database. The number of matched unique sequences and their total reads quickly increased 1 week after vaccination. Matched sequences included those bound to the Omicron strain and Omicron XBB sublineage. The antibody sequences that can bind to the Omicron strain and XBB sublineage revealed that the monovalent XBB.1.5 vaccines showed a stronger response than previous vaccines or SARS-CoV-2 infection before the emergence of XBB sublineage. The QASAS method was able to demonstrate the immunogenic effect of monovalent XBB.1.5 vaccines for the 2023-2024 COVID-19 vaccination campaign.
Next stepSign in for fit and contact guidance
Personalized fit, contact angles, and saved workflows require sign-in.